title: The antimicrobial activity and beta-lactamase stability of cefpirome, a new fourth-generation cephalosporin in comparison with other agents.
abstract: The antimicrobial activity of cefpirome was compared with amoxycillin/clavulanic acid, ampicillin/sulbactam, cefuroxime, ceftazidime, gentamicin and amikacin against 743 non-duplicate clinical isolates. MIC50 and MIC90 showed that the antibiotic was active against both Gram-negative and Gram-positive organisms. Cefpirome was highly active against most of the Enterobacteriaceae, including indole-positive Proteus spp., Aeromonas spp. (MIC < or = 1 mg/L) and Salmonella spp. (MIC < or = 0.5 mg/L). Neisseria gonorrhoeae and Haemophilus influenzae (including beta-lactamase producers) were all susceptible, with MIC less than 0.5 and 0.25 mg/L respectively. Cefpirome was more active than cefuroxime and ceftazidime against Campylobacter spp. (MIC < or = 2 mg/L), but less active than ceftazidime against Pseudomonas aeruginosa. Cefpirome was active against Streptococcus pneumoniae. Streptococcus bovis and coagulase-negative staphylococci (MIC < or = 0.5 mg/L) and methicillin-sensitive Staphylococcus aureus (MIC < or = 2 mg/L). Methicillin-resistant S. aureus, Gram-positive and Gram-negative anaerobes were resistant to cefpirome. The stability of cefpirome to TEM-1, TEM-2, PSE-1, SHV-1 and the chromosomal-mediated P99 and K-1 beta-lactamases was comparable to ceftazidime.
authors.affiliation: Department of Microbiology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories.
authors.forename: A F
authors.initials: AF
authors.lastname: Cheng
authors.forename: T K
authors.initials: TK
authors.lastname: Ling
authors.forename: A W
authors.initials: AW
authors.lastname: Lam
authors.forename: K S
authors.initials: KS
authors.lastname: Fung
authors.forename: R
authors.initials: R
authors.lastname: Wise
mesh_terms: D000150:Acinetobacter / Q000187:drug effects; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001419:Bacteria / Q000187:drug effects* / Q000235:genetics; D001421:Bacteria, Anaerobic / Q000187:drug effects; D001424:Bacterial Infections / Q000382:microbiology; D002511:Cephalosporins / Q000378:metabolism / Q000494:pharmacology*; D002954:Citrobacter / Q000187:drug effects; D004754:Enterobacter / Q000187:drug effects; D006088:Gram-Negative Aerobic Bacteria / Q000187:drug effects; D006094:Gram-Positive Bacteria / Q000187:drug effects; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D013211:Staphylococcus aureus / Q000187:drug effects; D014974:Xanthomonas / Q000187:drug effects; D001618:beta-Lactamases / Q000378:metabolism*; D000097572:Cefpirome
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D001618:beta-Lactamases; D000097572:Cefpirome